Prevention

The US Food and Drug Administration (FDA) has weighed in on the strains to be included in the 2018-2019 influenza vaccine.

In case you missed them, we’ve compiled the top five infectious disease articles from this past week.

The first global estimate of tuberculosis (TB) rates among young people find that about 1.8 million individuals in this age group develop the disease each year.

CARB-X, the international partnership between governmental and charitable groups in the United States and the United Kingdom, has announced new funding for the development of new antibiotics to fight drug-resistant bacteria.

The results of the trial revealed that the tablet reduced the rate of infection with influenza by 48%.

The institute has made the development of the vaccine “one of its highest priorities.”

A new bill introduced by a group of senators aims to boost universal flu vaccine research by $1 billion over the next 5 years, as health officials continue to investigate the cause of the flu shot’s low efficacy.

High prescribing continues despite the fact that heavy use of these agents can facilitate the development of multidrug-resistant bacteria and tendon, muscle, joint, and central nervous system damage.

NIAID Vaccine Research Center scientists alters broadly neutralizing HIV antibody to make it last longer in the blood.

A panel of experts in a recent symposium discuss how dental professionals can play an integral role in increasing HPV vaccination rates and decreasing HPV-related cancer.

Lingering historical concerns have led to inconsistent practices in antibiotic prophylaxis in this population.

Poignant study adds to the growing body of literature that points toward individualizing duration of therapy for each patient.

Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.

These studies lay clear the clinical and economic toll of cytomegalovirus in the allo-HCT setting.